Antibody drug conjugates in urological cancers: a review of the current landscape
Antibody drug conjugates in urological cancers: a review of the current landscape
Purpose of review: our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody–drug conjugate (ADC) development, emphasising their transformative potential in cancer care.
Recent findings: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape.
Summary: ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.
Antibody drug conjugate, Cancer, Chemotherapy, Prostate, Renal, Testicular, Urology, Urothelial
633-646
Ghose, Aruni
d7bad81c-a660-4497-b0f3-b0e8b077e5ee
Lapitan, Patricia
db9014b3-6737-4b01-8fc5-3b67a6e645a8
Apte, Vedika
7b93255d-fddf-4808-b93d-f60a5ea8f8a5
Ghosh, Adheesh
fd49665b-0684-4954-b4c4-3222c6f46d07
Kandala, Abhinav
96ae667b-3f22-421a-b82b-8d09acfdfa83
Basu, Sreejana
616d32cf-6954-494c-8b63-1d9d156bdf28
Parkes, Jo
68dd1dcc-5f79-429b-97c7-35386847b23d
Shinde, Sayali D.
cc119555-b3f5-4f6f-9332-254eb4f9e765
Boussios, Stergios
9fb2384c-458c-41a8-931a-016eeb7ac48b
Sharma, Anand
a56f46e7-b293-4dfb-a680-2d53ff8fe8cc
Das, Prantik
740de3ba-45ca-41d9-8411-849ceb9a3a00
Vasdev, Nikhil
8afb2cff-f10e-4fae-86c0-6d5624ed8cec
Rebuzzi, Sara E.
b0d4b453-8478-420f-a54c-7a8d0f041cdb
Ürün, Yüksel
73a268df-5499-4c00-9c83-5097785aa873
Kanesvaran, Ravindran
c8b3f14a-4d42-4343-8786-dff4aa87aa08
Maniam, Akash
0dad146a-4505-4a42-be6d-64965a1d8210
Banna, Giuseppe L.
b0919826-5c7b-4470-a15a-b754c1f05968
June 2024
Ghose, Aruni
d7bad81c-a660-4497-b0f3-b0e8b077e5ee
Lapitan, Patricia
db9014b3-6737-4b01-8fc5-3b67a6e645a8
Apte, Vedika
7b93255d-fddf-4808-b93d-f60a5ea8f8a5
Ghosh, Adheesh
fd49665b-0684-4954-b4c4-3222c6f46d07
Kandala, Abhinav
96ae667b-3f22-421a-b82b-8d09acfdfa83
Basu, Sreejana
616d32cf-6954-494c-8b63-1d9d156bdf28
Parkes, Jo
68dd1dcc-5f79-429b-97c7-35386847b23d
Shinde, Sayali D.
cc119555-b3f5-4f6f-9332-254eb4f9e765
Boussios, Stergios
9fb2384c-458c-41a8-931a-016eeb7ac48b
Sharma, Anand
a56f46e7-b293-4dfb-a680-2d53ff8fe8cc
Das, Prantik
740de3ba-45ca-41d9-8411-849ceb9a3a00
Vasdev, Nikhil
8afb2cff-f10e-4fae-86c0-6d5624ed8cec
Rebuzzi, Sara E.
b0d4b453-8478-420f-a54c-7a8d0f041cdb
Ürün, Yüksel
73a268df-5499-4c00-9c83-5097785aa873
Kanesvaran, Ravindran
c8b3f14a-4d42-4343-8786-dff4aa87aa08
Maniam, Akash
0dad146a-4505-4a42-be6d-64965a1d8210
Banna, Giuseppe L.
b0919826-5c7b-4470-a15a-b754c1f05968
Ghose, Aruni, Lapitan, Patricia, Apte, Vedika, Ghosh, Adheesh, Kandala, Abhinav, Basu, Sreejana, Parkes, Jo, Shinde, Sayali D., Boussios, Stergios, Sharma, Anand, Das, Prantik, Vasdev, Nikhil, Rebuzzi, Sara E., Ürün, Yüksel, Kanesvaran, Ravindran, Maniam, Akash and Banna, Giuseppe L.
(2024)
Antibody drug conjugates in urological cancers: a review of the current landscape.
Current Oncology Reports, 26 (6), .
(doi:10.1007/s11912-024-01524-7).
Abstract
Purpose of review: our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody–drug conjugate (ADC) development, emphasising their transformative potential in cancer care.
Recent findings: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape.
Summary: ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.
Text
ADC_Author_Manuscript217022141 (1)
- Accepted Manuscript
Restricted to Repository staff only until 23 April 2025.
Available under License Other.
Request a copy
More information
Accepted/In Press date: 25 March 2024
e-pub ahead of print date: 23 April 2024
Published date: June 2024
Keywords:
Antibody drug conjugate, Cancer, Chemotherapy, Prostate, Renal, Testicular, Urology, Urothelial
Identifiers
Local EPrints ID: 492374
URI: http://eprints.soton.ac.uk/id/eprint/492374
ISSN: 1523-3790
PURE UUID: dae7bace-33be-40ce-bb24-58254f42be35
Catalogue record
Date deposited: 25 Jul 2024 16:42
Last modified: 25 Jul 2024 16:42
Export record
Altmetrics
Contributors
Author:
Aruni Ghose
Author:
Patricia Lapitan
Author:
Vedika Apte
Author:
Adheesh Ghosh
Author:
Abhinav Kandala
Author:
Sreejana Basu
Author:
Jo Parkes
Author:
Sayali D. Shinde
Author:
Stergios Boussios
Author:
Anand Sharma
Author:
Prantik Das
Author:
Nikhil Vasdev
Author:
Sara E. Rebuzzi
Author:
Yüksel Ürün
Author:
Ravindran Kanesvaran
Author:
Akash Maniam
Author:
Giuseppe L. Banna
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics